Department of Urology, Central Hospital of Bolzano, Lorenz-Boehler street 5, 39100 Bolzano, Italy.
World J Urol. 2012 Dec;30(6):841-6. doi: 10.1007/s00345-012-0975-1. Epub 2012 Nov 10.
A second transurethral resection of the bladder (TURB) is recommended for high-grade bladder cancer (BC) yet yields negative results in over half of the cases. Aim of this study was to identify prognostic indicators of a positive second TURB or the need for a subsequent cystectomy.
The study cohort consisted of 101 patients with high-risk BC (T1G2-3, TaG3, Carcinoma in situ) who underwent second TURB after complete first resection. Age, gender, stage, grade, carcinoma in situ (Cis), tumour number, size, localization, surgeon experience and bladder wash cytology before the second TURB were considered as potential prognostic factors of positive histology at second TURB or the need for subsequent cystectomy.
The mean follow-up period was 23.8 months. The study cohort was comprised of 82 males and 17 females. Cytology on bladder wash urine was performed in 85/101 patients and in 39 was negative; 55.5 % of second TURB specimens were negative. The rate of upstaging to ≥T2 was 4.9 %. Cis (OR 8.4; 95 % CI 1.3-54.2; p = 0.03) and positive cytology (OR 6.8; 95 % CI 2.3-19.9; p = <0.01) were independent prognostic factors of a residual tumour in the second TURB. Cytology also correlated with clinical need for cystectomy in the follow-up (HR 6.5; 95 % CI 1.3-30.5; p = 0.02).
CIS and positive cytology prior to second TURB increased the risk of a positive second TURB specimen. A positive cytology also increases the risk of the subsequent need for cystectomy.
对于高级别膀胱癌(BC),推荐进行第二次经尿道膀胱肿瘤切除术(TURB),但超过一半的病例结果为阴性。本研究旨在确定第二次 TURB 阳性或需要后续行膀胱切除术的预后指标。
本研究队列包括 101 例高危 BC(T1G2-3、TaG3、原位癌)患者,在首次完全切除后行第二次 TURB。年龄、性别、分期、分级、原位癌(Cis)、肿瘤数量、大小、位置、术者经验以及第二次 TURB 前膀胱冲洗细胞学检查被认为是第二次 TURB 组织学阳性或需要后续行膀胱切除术的潜在预后因素。
平均随访时间为 23.8 个月。研究队列由 82 名男性和 17 名女性组成。101 例患者中有 85 例行膀胱冲洗细胞学检查,其中 39 例为阴性;55.5%的第二次 TURB 标本为阴性。升级为≥T2 的比例为 4.9%。Cis(OR 8.4;95%CI 1.3-54.2;p=0.03)和细胞学阳性(OR 6.8;95%CI 2.3-19.9;p<0.01)是第二次 TURB 标本中存在肿瘤残留的独立预后因素。细胞学检查也与随访中膀胱切除术的临床需求相关(HR 6.5;95%CI 1.3-30.5;p=0.02)。
第二次 TURB 前的 Cis 和细胞学阳性增加了第二次 TURB 标本阳性的风险。细胞学阳性也增加了后续行膀胱切除术的风险。